Previous Article | Next Article ![]()
Infect. Immun., Jun 1995, 2201-2205, Vol 63, No. 6
H Gazzano-Santoro, JB Parent, PJ Conlon, HG Kasler, CM Tsai, DA Lill-Elghanian and RI Hollingsworth
Both human bactericidal/permeability-increasing protein (BPI) and a
recombinant amino-terminal fragment of BPI (rBPI23) have been shown to bind
with high affinity to the lipid A region of lipopolysaccharide (LPS) (H.
Gazzano-Santoro, J. B. Parent, L. Grinna, A. Horwitz, T. Parsons, G.
Theofan, P. Elsbach, J. Weiss, and P. J. Conlon, Infect. Immun.
60:4754-4761, 1992). In the present study, lipid A preparations derived
from bacterial LPS as well as synthetic lipid A's and various lipid A
analogs were used to determine the structural elements required for rBPI23
binding. rBPI23 bound in vitro to a variety of synthetic and natural lipid
A preparations (both mono- and diphosphoryl forms), including lipid A's
prepared from Escherichia coli and Salmonella, Neisseria, and Rhizobium
species. Binding does not require that the origin of negative charge be
phosphate, since rBPI23 bound with high affinity to lipid A's isolated from
Rhizobium species that contain carboxylate (Rhizobium trifolii) or sulfate
(Rhizobium meliloti) anionic groups and lack phosphate. Lipid A acyl chains
are important, since rBPI23 did not bind to four synthetic variants of the
beta(1-6)- linked D-glucosamine disaccharide lipid A head group, all devoid
of acyl chains. rBPI23 also bound weakly to lipid X, a monosaccharide lipid
precursor of LPS corresponding to the reducing half of lipid A. Lipid IVA,
a precursor identical to E. coli lipid A except that it lacks the 2' and 3'
acyl chains, was the simplest structure identified in this study that
rBPI23 bound with high affinity. These results demonstrate that rBPI23 has
a binding specificity for the lipid A region of LPS and binding involves
both electrostatic and hydrophobic components.
Copyright © 1995, American Society for Microbiology
Characterization of the structural elements in lipid A required for binding of a recombinant fragment of bactericidal/permeability- increasing protein rBPI23 [published erratum appears in Infect Immun 1995 Dec;63(12):4967]
Sepsis Research Department, XOMA Corporation, Berkeley, California 94710, USA.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|